- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04394858
Testowanie dodania leku przeciwnowotworowego, olaparybu, do zwykłej chemioterapii (temozolomid) zaawansowanego raka neuroendokrynnego
Prospektywne, wieloinstytucjonalne badanie fazy II oceniające temozolomid w porównaniu z temozolomidem i olaparybem w leczeniu zaawansowanego guza chromochłonnego i przyzwojaka
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate [ADP]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone.
Przegląd badań
Status
Warunki
- Guz chromochłonny nadnerczy z przerzutami
- Paraganglioma z przerzutami
- Nieoperacyjny guz chromochłonny nadnerczy
- Nieoperacyjny paraganglioma
- Zaawansowany guz chromochłonny nadnerczy
- Zaawansowany paraganglioma
- Stopień III guz chromochłonny nadnerczy i przyzwojak współczulny AJCC v8
- Guz chromochłonny nadnerczy w stadium IV i przyzwojak współczulny AJCC v8
Szczegółowy opis
PRIMARY OBJECTIVE:
I. To compare the progression-free survival (PFS) of patients with advanced pheochromocytoma and paraganglioma (APP) receiving temozolomide (dose dense) and olaparib to that of patients receiving temozolomide (pulse dose) alone.
SECONDARY OBJECTIVES:
I. To compare the overall survival (OS) of patients with APP receiving temozolomide (dose dense) and olaparib versus (vs.) temozolomide (pulse dose) alone.
II. To compare the objective response rate (ORR) associated with temozolomide (dose dense) and olaparib vs. temozolomide (pulse dose) alone in patients with APP.
III. To evaluate and compare the toxicity profile of temozolomide-based combinations (temozolomide [dose dense] and olaparib vs. temozolomide [pulse dose]) in patients with APP using Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE.
OTHER OBJECTIVE:
I. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
EXPLORATORY OBJECTIVES:
I. To assess biochemical response: serum catecholamines and metanephrines; urine catecholamines and metanephrines.
II. To assess biomolecular markers associated with clinical outcome: germline succinyl dehydrogenase (SDH) mutations and tumor status of the repair enzyme methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive temozolomide orally (PO) once daily (QD) and olaparib PO twice daily (BID) on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with contrast or magnetic resonance imaging (MRI) throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
ARM II: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
Patients discontinuing treatment due to reasons other than disease progression are followed every 12 weeks until disease progression, then every 6 months until 5 years after registration. Patients discontinuing treatment due to disease progression are followed every 6 months for 5 years after registration.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alaska
-
Anchorage, Alaska, Stany Zjednoczone, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Stany Zjednoczone, 99504
- Anchorage Radiation Therapy Center
-
-
California
-
Burbank, California, Stany Zjednoczone, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
-
Florida
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33308
- Holy Cross Hospital
-
Gainesville, Florida, Stany Zjednoczone, 32610
- UF Health Cancer Institute - Gainesville
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Stany Zjednoczone, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stany Zjednoczone, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Stany Zjednoczone, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Stany Zjednoczone, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Stany Zjednoczone, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Stany Zjednoczone, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Stany Zjednoczone, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago Comprehensive Cancer Center
-
Danville, Illinois, Stany Zjednoczone, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Stany Zjednoczone, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Stany Zjednoczone, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Stany Zjednoczone, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Stany Zjednoczone, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Stany Zjednoczone, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Stany Zjednoczone, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Stany Zjednoczone, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Stany Zjednoczone, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Stany Zjednoczone, 60462
- University of Chicago Medicine-Orland Park
-
Ottawa, Illinois, Stany Zjednoczone, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Stany Zjednoczone, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stany Zjednoczone, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Stany Zjednoczone, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Stany Zjednoczone, 61356
- Illinois CancerCare-Princeton
-
Urbana, Illinois, Stany Zjednoczone, 61801
- Carle Cancer Center
-
Washington, Illinois, Stany Zjednoczone, 61571
- Illinois CancerCare - Washington
-
-
Maryland
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- National Institutes of Health Clinical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Dana-Farber Cancer Institute
-
Newton, Massachusetts, Stany Zjednoczone, 02467
- Dana-Farber Cancer Institute - Chestnut Hill
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Stany Zjednoczone, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Stany Zjednoczone, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Stany Zjednoczone, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Stany Zjednoczone, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Stany Zjednoczone, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Stany Zjednoczone, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Stany Zjednoczone, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Stany Zjednoczone, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Stany Zjednoczone, 48346
- Newland Medical Associates-Clarkston
-
Detroit, Michigan, Stany Zjednoczone, 48236
- Henry Ford Health Saint John Hospital
-
East China Township, Michigan, Stany Zjednoczone, 48054
- Henry Ford River District Hospital
-
Flint, Michigan, Stany Zjednoczone, 48503
- Hurley Medical Center
-
Flint, Michigan, Stany Zjednoczone, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Stany Zjednoczone, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Stany Zjednoczone, 48503
- Cancer Hematology Centers - Flint
-
Grosse Pointe Woods, Michigan, Stany Zjednoczone, 48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods, Michigan, Stany Zjednoczone, 48236
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods, Michigan, Stany Zjednoczone, 48236
- Henry Ford Saint John Hospital - Van Elslander
-
Lansing, Michigan, Stany Zjednoczone, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Stany Zjednoczone, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Stany Zjednoczone, 48154
- Hope Cancer Clinic
-
Macomb, Michigan, Stany Zjednoczone, 48044
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb, Michigan, Stany Zjednoczone, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Marlette, Michigan, Stany Zjednoczone, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Hope Cancer Center
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Rochester Hills, Michigan, Stany Zjednoczone, 48309
- Henry Ford Rochester Hospital
-
Saginaw, Michigan, Stany Zjednoczone, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stany Zjednoczone, 48601
- MyMichigan Medical Center Saginaw
-
Sterling Heights, Michigan, Stany Zjednoczone, 48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City, Michigan, Stany Zjednoczone, 48764
- MyMichigan Medical Center Tawas
-
Warren, Michigan, Stany Zjednoczone, 48088
- Advanced Breast Care Center PLLC
-
Warren, Michigan, Stany Zjednoczone, 48093
- Macomb Hematology Oncology PC
-
Warren, Michigan, Stany Zjednoczone, 48093
- Henry Ford Madison Heights Hospital - Breast
-
Warren, Michigan, Stany Zjednoczone, 48093
- Henry Ford Health Warren Hospital
-
Warren, Michigan, Stany Zjednoczone, 48093
- Henry Ford Warren Hospital - GLCMS
-
West Branch, Michigan, Stany Zjednoczone, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Stany Zjednoczone, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Stany Zjednoczone, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Burnsville, Minnesota, Stany Zjednoczone, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Stany Zjednoczone, 55337
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Stany Zjednoczone, 55008
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Stany Zjednoczone, 55433
- Mercy Hospital
-
Edina, Minnesota, Stany Zjednoczone, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Stany Zjednoczone, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Stany Zjednoczone, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Stany Zjednoczone, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Stany Zjednoczone, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Stany Zjednoczone, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Stany Zjednoczone, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Stany Zjednoczone, 55454
- Health Partners Inc
-
Monticello, Minnesota, Stany Zjednoczone, 55362
- Monticello Cancer Center
-
New Ulm, Minnesota, Stany Zjednoczone, 56073
- New Ulm Medical Center
-
Princeton, Minnesota, Stany Zjednoczone, 55371
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Stany Zjednoczone, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Stany Zjednoczone, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stany Zjednoczone, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Stany Zjednoczone, 55102
- United Hospital
-
Shakopee, Minnesota, Stany Zjednoczone, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Stany Zjednoczone, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Stany Zjednoczone, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Stany Zjednoczone, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Stany Zjednoczone, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Stany Zjednoczone, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Cape Girardeau, Missouri, Stany Zjednoczone, 63703
- Saint Francis Medical Center
-
-
Montana
-
Missoula, Montana, Stany Zjednoczone, 59802
- Saint Patrick Hospital - Community Hospital
-
-
New Jersey
-
Basking Ridge, New Jersey, Stany Zjednoczone, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Stany Zjednoczone, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Stany Zjednoczone, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Albany, New York, Stany Zjednoczone, 12208
- Albany Medical Center
-
Commack, New York, Stany Zjednoczone, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Stany Zjednoczone, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Stany Zjednoczone, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Stany Zjednoczone, 11553
- Memorial Sloan Kettering Nassau
-
-
Ohio
-
Columbus, Ohio, Stany Zjednoczone, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Oklahoma
-
Lawton, Oklahoma, Stany Zjednoczone, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Bend, Oregon, Stany Zjednoczone, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Stany Zjednoczone, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Stany Zjednoczone, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Stany Zjednoczone, 97420
- Bay Area Hospital
-
Newberg, Oregon, Stany Zjednoczone, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Stany Zjednoczone, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health and Science University
-
Portland, Oregon, Stany Zjednoczone, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Stany Zjednoczone, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stany Zjednoczone, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Stany Zjednoczone, 18017
- Lehigh Valley Hospital - Muhlenberg
-
East Stroudsburg, Pennsylvania, Stany Zjednoczone, 18301
- Pocono Medical Center
-
Hazleton, Pennsylvania, Stany Zjednoczone, 18201
- Lehigh Valley Hospital-Hazleton
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78723
- Dell Children's Medical Center of Central Texas
-
-
Utah
-
Farmington, Utah, Stany Zjednoczone, 84025
- Farmington Health Center
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84106
- University of Utah Sugarhouse Health Center
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- University of Virginia Cancer Center
-
-
Washington
-
Aberdeen, Washington, Stany Zjednoczone, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Stany Zjednoczone, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Stany Zjednoczone, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Stany Zjednoczone, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Stany Zjednoczone, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Stany Zjednoczone, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Stany Zjednoczone, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Stany Zjednoczone, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Stany Zjednoczone, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, Stany Zjednoczone, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Stany Zjednoczone, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Stany Zjednoczone, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Stany Zjednoczone, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Stany Zjednoczone, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Stany Zjednoczone, 98584
- Providence Regional Cancer System-Shelton
-
Vancouver, Washington, Stany Zjednoczone, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Stany Zjednoczone, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Stany Zjednoczone, 98597
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
New Richmond, Wisconsin, Stany Zjednoczone, 54017
- Cancer Center of Western Wisconsin
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Documentation of disease
- Histologic documentation: Histologically-proven advanced (metastatic or unresectable primary) pheochromocytoma or paraganglioma
- Stage: Advanced (metastatic or unresectable primary) disease
- Tumor site: Histologically-proven pheochromocytoma or paraganglioma
- Radiographic evaluation: Radiographic evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 in the 12 months prior to registration
-
Measurable disease
- Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes). Non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
-
Prior treatment with other somatostatin analog, chemotherapy, radiotherapy (including peptide radionuclide receptor therapy [PRRT]), or surgery must be completed >= 28 days prior to registration. Patients must have recovered from any effects of any major surgery prior to registration
-
Prior treatment with radiolabeled metaiodobenzylguanidine (MIBG) must be completed >= 12 weeks prior to registration and lifetime cumulative 131I-MIBG dose must be < 1000 MBq kg^-1 (36 mCi kg^-1)
-
Prior treatment with antibiotics must be completed >= 7 days prior to registration
-
No prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor
-
No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
-
Contraception
- Therapy utilized in this trial is associated with medium/high fetal risk
- Women of childbearing potential and their partners, who are sexually active, must agree to use two highly effective forms of contraception in combination. This should be started from the time of registration and continue throughout the period of taking study treatment and for at least 1 month after last dose of study drug(s), or they must totally/truly abstain from any form of sexual intercourse
- Male patients must use a condom during treatment and for 3 months after the last dose of study drug(s) when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. Male patients should not donate sperm throughout the period of taking study drug(s) and for 3 months following the last dose of study drug(s)
-
Age >= 12 years
-
Eastern Cooperative Oncology Group (ECOG) Patients ≥ 18 years of age: Performance status: 0-2
- Patients < 16 years of age: Lansky ≥ 50%
- Patients 16 to < 18 years of age: Karnofsky ≥ 50%
- Patients ≥ 18 years of age: ECOG performance status ≤ 2
-
Absolute neutrophil count >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Hemoglobin >= 10 mg/dL if prior radionuclide therapy Hemoglobin >= 8 mg/dL if no prior radionuclide therapy
- In the absence of transfusion within the previous 24 hours. Radionuclide therapy includes PRRT or MIBG
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Except in the case of Gilbert's syndrome, then total bilirubin must be =< 3.0 x ULN
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN
-
Creatinine < 1.5 x ULN OR calculated (calc.) creatinine clearance > 50 mL/min
-
Calculated by Cockcroft-Gault equation
-
By Cockcroft-Gault equation. Alternatively, for patients < 18 years of age, maximum serum creatinine ≤ the below age-sex-specific norms:
- Age 12 years: Male 1.2; female 1.2
- Age 13 to < 16 years: Male 1.5; female 1.4
- Age 16 to < 18 years: Male 1.7; female 1.4
-
-
No indication of uncontrolled, potentially reversible cardiac condition(s) as determined by investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's formula-corrected QT interval [QTcF] prolongation > 500 msec, electrolyte disturbances, etc.) and no known congenital long QT syndrome
-
No extensive bilateral lung disease or pneumonitis
-
No abnormal organ or bone marrow function =< 28 days prior to registration
-
Patients with human immunodeficiency virus (HIV) positivity are allowed if CD4 count > 250 cells/uL and they have an undetectable HIV viral load within 6 months of registration
-
No active infection
-
No history of myelodysplastic syndrome (MDS) (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia
-
No known gastrointestinal condition(s) that might predispose for drug intolerability or poor drug absorption
-
No known medical condition causing an inability to swallow oral formulations of agents
-
No history of allergic reaction attributed to compounds of similar chemical or biologic composition to PARP inhibitors
-
Concurrent use of combination antiretroviral therapy (ART) is not permitted
-
Chronic concomitant treatment with strong or moderate CYP3A4 inducers or inhibitors is not allowed. Patients must discontinue the agent(s) >= 21 days prior to registration; enzalutamide and/or phenobarbital must be discontinued >= 5 weeks prior to registration
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Arm I (temozolomide, olaparib)
Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. |
Ancillary studies
Inne nazwy:
Undergo MRI
Inne nazwy:
Given PO
Inne nazwy:
Undergo collection of blood samples
Inne nazwy:
Given PO
Inne nazwy:
Undergo CT with contrast
Inne nazwy:
|
|
Aktywny komparator: Arm II (temozolomide)
Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. |
Ancillary studies
Inne nazwy:
Undergo MRI
Inne nazwy:
Given PO
Inne nazwy:
Undergo collection of blood samples
Inne nazwy:
Undergo CT with contrast
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression-free survival (PFS)
Ramy czasowe: From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years
|
Will be compared between treatment arms using the un-stratified log-rank test at one-sided level of 0.11 and the p-value will be used for decision making. The hazard ratio will be estimated using a Cox proportional hazards model and the 95% confidence interval for the hazard ratio will be provided. Results from a stratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer-Crowley methodology will be used to construct the 95% confidence interval for the median PFS for each treatment arm. |
From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall survival (OS)
Ramy czasowe: From randomization to death due to any cause, assessed up to 5 years
|
Patients who are alive will be censored at last follow-up. The distribution of survival time will be estimated using the method of Kaplan-Meier. OS will be compared between treatment arms using the log-rank test. OS medians, survival rates and hazard ratio will be estimated along with 95% confidence intervals. |
From randomization to death due to any cause, assessed up to 5 years
|
|
Objective response
Ramy czasowe: Up to 5 years
|
Will be assessed by RECIST version 1.1 criteria. Will be estimated using objective response rate where objective response rate is defined as the number of evaluable patients achieving a response (partial response or complete response per RECIST version 1.1) during treatment with study therapy divided by the total number of evaluable patients. Rates of response will be compared across arms using a Chi-Square Test for Proportion. Point estimates will be generated for objective response rates within each arm along with 95% binomial confidence intervals. |
Up to 5 years
|
|
Incidence of adverse events
Ramy czasowe: Up to 5 years
|
Will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The term toxicity is defined as adverse events that are classified as possibly, probably, or definitely related to study treatment. Toxicities will be evaluated via the ordinal Common Terminology Criteria for Adverse Events standard toxicity grading. Similarly, scores (0-4) and the maximum score for each Patient-Reported Outcomes-CTCAE item will be recorded for each patient. |
Up to 5 years
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Biochemical response
Ramy czasowe: Up to 5 years
|
Levels of chromogranin A, urine and/or plasma catecholamines and metanephrines may predict response to therapy. The proportion of patients with a biochemical response of partial response or better, as determined by plasma and/or urine catecholamines and metanephrines, will be calculated, and a 95% confidence interval will be placed on this proportion. For each factor, we will calculate the mean +/- standard deviation, minimum, maximum, and quartiles; in addition, we will generate box and whisker plot. |
Up to 5 years
|
|
Biomolecular markers associated with clinical outcome
Ramy czasowe: Up to 5 years
|
Will analyze for methyltransferase (MGMT) methylation expression in archival tumors and correlate with the radiographic response rate in metastatic pheochromocytoma/paraganglioma. This is hypothesis generated box and whisker plot. |
Up to 5 years
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Jaydira Del Rivero, Alliance for Clinical Trials in Oncology
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Guzy neuroendokrynne
- Guz chromochłonny
- Przyzwojak
- Organiczne chemikalia
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Techniki śledcze
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Azole
- Działania farmakologiczne
- Działania i zastosowania chemiczne
- Dacarbazine
- Triazennes
- Imidazoles
- Specjalne zastosowania chemikaliów
- Techniki chemii, analityczne
- Analiza widma
- Diagnostyczne zastosowania chemikaliów
- Temozolomid
- Prowadzenie okazów
- Spektroskopia rezonansu magnetycznego
- Olaparib
- Contrast Media
Inne numery identyfikacyjne badania
- NCI-2020-03379
- U10CA180821 (Grant/umowa NIH USA)
- NCI-2020-03379 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- A021804 (Inny identyfikator: CTEP)
- A021804 (Inny identyfikator: Alliance for Clinical Trials in Oncology)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .